What changed
FACT (cited rule): On 2026-06-17 FDA classified 'radiological machine learning-based quantitative imaging software with predetermined change control plan' into Class II with special controls, making the PCCP part of the device type's codified regulatory identity. INFERENCE: every new entrant in this device category must now produce a PCCP at submission time to use the pathway.
Why now
The rule is weeks old, so no incumbent tooling is entrenched for this specific device type. The PCCP is revenue-gating for filers: without it they cannot ship post-clearance model updates without new 510(k)s. HYPOTHESIS: small AI-imaging firms are the most constrained by per-update 510(k) costs and will adopt the pathway fastest.
Converging signals
One FORCED BUYER signal: the Federal Register classification rule (2026-12166). No PAIN or HIRING/SPEND evidence was provided — the demand picture rests on a single (strong) regulatory signal plus inference. The 'signals' array is empty; this convergence is hypothesis-led.
Customer pain
HYPOTHESIS (no direct complaint evidence supplied): small AI-imaging startups lack in-house regulatory affairs staff; authoring a PCCP (modification protocol, validation methodology, data management, impact assessment) against the new special controls is procedural know-how they must buy or slowly self-teach, and getting it wrong risks an NSE/deficiency letter that delays clearance by months.
Who pays
Founders/heads-of-regulatory at sub-50-person AI medical-imaging software companies preparing a 510(k) under the new classification, plus RA consultants serving several such clients who want leveraged tooling. Willingness to pay is inferred from the general market rate for RA consulting, not from supplied evidence.
Solved today
FACT-ADJACENT (general knowledge, not in supplied evidence): regulatory consultancies and RA contractors author PCCPs bespoke; FDA's 2023 PCCP guidance provides free but unopinionated scaffolding; QMS/regulatory platforms (Greenlight Guru, Rimsys, Ketryx) sell adjacent lifecycle tooling priced for funded medtech.
Why current solutions are bad
Bespoke consulting is slow and reportedly $20k+ (HYPOTHESIS — the input itself flags this as needing interview confirmation). Free guidance tells you what sections must exist, not what defensible language keyed to the new special controls looks like. Adjacent platforms are QMS-wide and enterprise-priced, not a focused PCCP authoring product.
Proposed product
'PCCP Studio': (1) a guided PCCP builder whose structure mirrors the special controls in the new classification; (2) a library of modification-protocol and validation-methodology language patterns keyed to update types (retraining on new data, threshold changes, architecture-constant weight updates); (3) post-clearance update-log tooling that checks each proposed model change against the approved change envelope and generates the documentation trail. Sold as subscription with a one-time authoring tier.
MVP version
A structured PCCP document builder (web form → generated draft) covering the four core sections, seeded with language patterns derived from the codified special controls, the 2023 PCCP guidance, and published cleared-device summaries — reviewed once by a contracted RA/QA consultant (founder has capital for this). Plus a landing page running the stated waitlist test.
30-day build
Run the validation test BEFORE building: landing page + posts in r/medicaldevices, RAPS forums, LinkedIn medtech-regulatory groups; 8-10 interviews with small AI-imaging firms and independent RA consultants to confirm (a) consultancy PCCP quotes, (b) whether the 2023 guidance alone suffices, (c) whether fixed-price templates already exist for the small tier. Contract one credentialed RA consultant as content reviewer/named advisor.
60-day build
If ≥10 qualified signups or ≥3 pilot commitments: build the MVP builder + language library; pre-sell 3 paid pilots ($2.5-5k each, authoring-tier) to firms with submissions in flight; use pilots to harden the templates against real FDA pre-sub feedback.
90-day revenue plan
Convert pilots to case studies; open $399-799/mo subscriptions (builder + change-envelope log) and a $7.5k assisted-authoring tier fulfilled with the contracted RA consultant. Secondary channel: license the toolkit to independent RA consultants at a multi-client seat price.
Distribution path
RAPS community, LinkedIn medtech-regulatory groups, r/medicaldevices, imaging-AI conference circuits (SIIM, RSNA vendor lists as a prospect database — FDA 510(k) database and the new product code give a self-updating list of exactly who is filing). Demonstrated-value sales via a free 'PCCP readiness checklist' lead magnet fits founder's style.
Pricing hypothesis
$399-799/mo subscription; $7.5k one-time assisted authoring; $1.5k/yr per-client consultant license. Anchor against $20k+ bespoke consulting (anchor itself is unverified — confirm in interviews).
Technical difficulty
Software is easy (forms, doc generation, rules-checking log). The hard part is content credibility: defensible regulatory language requires paid RA expertise the founder must contract in — affordable now, but it is the product's core, not the code.
Legal / regulatory risk
Moderate and real: the product edges toward regulatory advice for FDA submissions. Mitigate with 'tooling + templates, not advice' positioning, a named RA advisor, and disclaimers — but a customer whose submission is rejected may blame the templates. Not selling a medical device itself, so no FDA clearance needed for the product.
Platform dependency
Low. Depends on FDA policy stability; PCCPs are statutory (FDORA 2022) and expanding across device types, so the substrate is durable.
Founder fit
Mixed — weaker than it pattern-matches. The FMCSA edge was automating submissions INTO a government portal and charging per transaction; here there is no portal-automation layer — the value is regulatory authoring know-how in a domain (FDA medical devices) the founder has explicitly avoided and has no credibility in. The forced-buyer/mandate shape fits the lesson-confirmed heuristic (conf 0.80), but the delivery mechanism (expert document product to medtech buyers with long trust cycles) does not play to demonstrated strengths. Fit is rescued only partly by capital to hire RA expertise.
Breakout potential
Good if it works: PCCP requirements extend across SaMD categories (cardiology ML, pathology, etc.), so a radiology wedge can expand device-type by device-type; the change-envelope log is recurring-revenue lock-in after clearance.
Final recommendation
DO NOT BUILD YET — run the cheap validation gate first. The forced-buyer mandate is real and freshly minted, but demand beyond the single rule is unevidenced, the buyer's trust bar is high, and founder fit is mediocre (no medtech RA credibility; no portal-automation wedge). Spend ≤$500 and 7-10 days on the landing-page + interview test the hypothesis itself specifies. Proceed only if ≥3 paid pilot commitments materialize AND interviews confirm consultancy quotes >$15k with no existing fixed-price template product; otherwise archive and keep the pattern ('authorization outruns capability') for domains closer to the founder's credibility.
Next action
Ship the landing page and post in RAPS/LinkedIn/r/medicaldevices this week; in parallel, pull the FDA 510(k) database for the new product code and cold-contact the first small-company filers for 15-minute interviews about how they produced their PCCP and what it cost.